Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia

The Utility of BRAF V600E Mutation-Specific Antibody VE1 for the Diagnosis of Hairy Cell Leukemia

“…3 Since the seminal report by Tiacci et al, various studies have confirmed that BRAF V600E is present in nearly all HCL and is present at a very low frequency or is entirely absent in other mature B-cell lymphoproliferative disorders. [4][5][6][7] The discovery of BRAF V600E mutation in HCL has opened a new era in which the diagnostic and therapeutic paradigms of HCL have shifted.…”

Rare Lymphomas

“…Exploration of other molecular factors as BRAF V600E became of interest as this mutation is also occasionally found in B-PLL (Langabeer et al 2012 ) and BRAF inhibitors, e.g., vemurafenib became available in other malignancies and have shown proof-of-principle activity in hairy-cell leukemia carrying the BRAF V600E mutation (Dietrich et al 2012 ). Exploration of other molecular factors as BRAF V600E became of interest as this mutation is also occasionally found in B-PLL (Langabeer et al 2012 ) and BRAF inhibitors, e.g., vemurafenib became available in other malignancies and have shown proof-of-principle activity in hairy-cell leukemia carrying the BRAF V600E mutation (Dietrich et al 2012 ).…”

BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia

“…43 However, the numbers of BRAF-mutant leukemias, lymphomas, and myelomas identified are increasing because of broader and deeper sequencing efforts. 18,19,44,45 Besides increased growth and decreased apoptosis, an established effect of aberrantly activated MAPK in 14 NOVEMBER 2017 x VOLUME 1, NUMBER 46,47 In melanoma models in vitro, selective BRAF V600E inhibition improves T-cell recognition of tumors.…”